Table 5.
Multivariate Cox Regression Analysis for Clinicopathologic Parameters and Immunohistochemical Expression of VAV3 and FOXA2
| No. of cases (n=74) | Death | Overall survival | Hazard ratio | P-value | |
|---|---|---|---|---|---|
| Age | |||||
| <55 | 42 | 9 | 35.0±29.7 | 2.38 | 0.134 |
| ≥55 | 32 | 12 | 26.5±23.1 | ||
| Clinical stage | |||||
| I/II | 14 | 1 | 38.8±24.2 | 3.83 | 0.220 |
| III/IV | 60 | 20 | 29.6±27.7 | ||
| Distant metastasis | |||||
| Absent | 38 | 10 | 38.6±27.1 | 1.10 | 0.877 |
| Present | 36 | 11 | 23.6±25.4 | ||
| Chemoresistance | |||||
| Sensitive | 55 | 13 | 37.0±29.1 | 17.74 | <0.05a |
| Resistant | 19 | 8 | 15.0±9.1 | ||
| VAV3 expression | |||||
| Low | 18 | 1 | 33.1±27.5 | 15.27 | <0.05a |
| High | 56 | 20 | 30.8±27.3 | ||
| FOXA2 expression | |||||
| Low | 25 | 3 | 33.0±30.5 | 2.51 | 0.222 |
| High | 49 | 18 | 30.5±25.6 | ||
a
, p<0.05.